Overview

A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Status:
Completed
Trial end date:
2019-10-22
Target enrollment:
Participant gender:
Summary
Double-blind, Placebo-controlled study to evaluate the dose-response relationship of safety, efficacy and pharmacokinetics of MA13A9 in hemodialysis patients with pruritus.
Phase:
Phase 2
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Collaborator:
Maruishi Pharmaceutical